Achieving this milestone keeps the clinical development of GlycoDesign's cardiovascular disease program on schedule.
Thrombosis is a major cause of life-threatening cardiovascular diseases.
Venous thrombosis occurs typically after major surgery or with serious chronic illness and can cause pulmonary embolism. Thrombosis in arteries can cause heart attacks and strokes. This collaboration combines GlycoDesign's expertise in cardiovascular research with Leo's manufacturing capability, experience developing and marketing heparin-based therapeutics in Europe, and its marketing presence in Canada. The companies are seeking a third party pharmaceutical company to support the further development and commercialization of these drug candidates. GlycoDesign Inc. is a world leader in the discovery, development and delivery of glycotherapeutics for the treatment of infectious diseases, cancer, cardiovascular disease and inflammatory diseases.